All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' reply
Lancet Haematol
.
2023 Sep;10(9):e707.
doi: 10.1016/S2352-3026(23)00242-9.
Authors
Hartmut Döhner
1
,
Axel Benner
2
,
Arnold Ganser
3
Affiliations
1
Department of Internal Medicine III, Ulm University Hospital, Ulm 89081, Germany. Electronic address: hartmut.doehner@uniklinik-ulm.de.
2
Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
3
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
PMID:
37652598
DOI:
10.1016/S2352-3026(23)00242-9
No abstract available
Publication types
Letter
Comment
MeSH terms
Clinical Trials as Topic
Gemtuzumab* / therapeutic use
Humans
Longitudinal Studies
Substances
Gemtuzumab